JP2004502408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502408A5 JP2004502408A5 JP2001572548A JP2001572548A JP2004502408A5 JP 2004502408 A5 JP2004502408 A5 JP 2004502408A5 JP 2001572548 A JP2001572548 A JP 2001572548A JP 2001572548 A JP2001572548 A JP 2001572548A JP 2004502408 A5 JP2004502408 A5 JP 2004502408A5
- Authority
- JP
- Japan
- Prior art keywords
- altered peptide
- peptide
- cells
- peptides
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 101001013022 Homo sapiens Migration and invasion enhancer 1 Proteins 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010066345 MHC binding peptide Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000900711 Mus musculus GRB2-related adaptor protein 2 Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19446300P | 2000-04-04 | 2000-04-04 | |
| PCT/US2001/010855 WO2001074859A2 (en) | 2000-04-04 | 2001-04-04 | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502408A JP2004502408A (ja) | 2004-01-29 |
| JP2004502408A5 true JP2004502408A5 (enExample) | 2008-05-22 |
Family
ID=22717696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572548A Pending JP2004502408A (ja) | 2000-04-04 | 2001-04-04 | 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7268207B2 (enExample) |
| EP (1) | EP1272636B8 (enExample) |
| JP (1) | JP2004502408A (enExample) |
| CN (2) | CN1610743A (enExample) |
| AT (1) | ATE404669T1 (enExample) |
| AU (2) | AU2001253119B2 (enExample) |
| CA (1) | CA2413211A1 (enExample) |
| DE (1) | DE60135315D1 (enExample) |
| NZ (1) | NZ522282A (enExample) |
| WO (1) | WO2001074859A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413211A1 (en) * | 2000-04-04 | 2001-10-11 | University Of Rochester | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| US7135278B1 (en) | 2000-09-29 | 2006-11-14 | University Of Rochester | Method of screening for therapeutics for infectious diseases |
| EP1359937A4 (en) * | 2001-02-14 | 2004-07-28 | Genzyme Corp | MODIFIED PEPTIDE LIGANDS |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP2070949B1 (en) * | 2002-06-10 | 2013-01-16 | Vaccinex, Inc. | C35 antibodies and their use in the treatment of cancer |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| US20040210037A1 (en) * | 2003-03-28 | 2004-10-21 | Vaccinex, Inc. | Targeted MHC class I alpha3 vaccine delivery systems |
| WO2005099361A2 (en) * | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| US20050158323A1 (en) * | 2003-12-04 | 2005-07-21 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| WO2005106044A1 (en) * | 2004-04-23 | 2005-11-10 | Exagen Diagnostics, Inc. | Compositions and methods for breast cancer prognosis |
| CN101505793A (zh) * | 2006-06-22 | 2009-08-12 | 瓦西尼斯公司 | 用于治疗癌症的抗c35抗体 |
| AU2008219020B2 (en) * | 2007-02-21 | 2013-08-22 | Vaccinex, Inc. | Modulation of NKT cell activity with antigen-loaded CDId molecules |
| JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| US8637026B2 (en) | 2007-12-26 | 2014-01-28 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
| PT2385980T (pt) | 2009-01-08 | 2018-06-26 | Albert Einstein College Medicine Inc | Vacinas bacterianas com glicolípidos do tipo ceramida associados à parede celular e utilização dos mesmos |
| WO2010111792A1 (en) * | 2009-04-01 | 2010-10-07 | The University Of British Columbia | Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses |
| CN102639555B (zh) * | 2009-09-24 | 2015-11-25 | 加利福尼亚大学董事会 | 膀胱癌特异性配体肽 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| MX2018007204A (es) * | 2015-12-16 | 2018-12-11 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno. |
| IL273030B2 (en) * | 2017-09-05 | 2024-03-01 | Gritstone Bio Inc | Neoantigen identification for t-cell therapy |
| AU2018348165B2 (en) | 2017-10-10 | 2025-09-04 | Seattle Project Corp. | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| WO2019199579A1 (en) | 2018-04-09 | 2019-10-17 | The Board Of Trustees Of The Leland Stanford Junior University | Method of in situ gene sequencing |
| KR102318018B1 (ko) | 2019-07-05 | 2021-10-28 | 한국생산기술연구원 | 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드 |
| IL292313A (en) * | 2019-10-18 | 2022-06-01 | Univ Leland Stanford Junior | Clinical- and industrial-scale intact-tissue sequencing |
| CN115407064B (zh) * | 2021-05-26 | 2025-09-23 | 复旦大学附属肿瘤医院 | 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0581600A (ja) * | 1991-04-18 | 1993-04-02 | Fujitsu Ltd | 双曲線航法システムにおけるシステム監視処理方式 |
| CA2141960A1 (en) | 1992-08-07 | 1994-02-17 | Ralph T. Kubo | Hla binding peptides and their uses |
| EP0703783B1 (en) | 1993-03-05 | 2010-05-05 | Epimmune Inc. | Methods of making immunogenic hla-a2.1 binding peptides |
| US5856131A (en) * | 1997-02-24 | 1999-01-05 | Incyte Pharmaceuticals, Inc. | Human selenoprotein |
| US7026447B2 (en) * | 1997-10-09 | 2006-04-11 | Human Genome Sciences, Inc. | 53 human secreted proteins |
| JP2002507387A (ja) * | 1997-12-24 | 2002-03-12 | コリクサ コーポレイション | 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法 |
| AU2342299A (en) * | 1998-01-26 | 1999-08-09 | Genquest Inc. | Compositions and methods for detecting and treating breast cancer |
| US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| CA2392510A1 (en) * | 1999-11-30 | 2001-06-07 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
| CA2413211A1 (en) * | 2000-04-04 | 2001-10-11 | University Of Rochester | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| EP1274852A2 (en) | 2000-04-12 | 2003-01-15 | University Of Rochester | Targeted vaccine delivery systems |
| DE60126130T2 (de) * | 2000-11-17 | 2007-10-18 | The University Of Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
| US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| EP2070949B1 (en) * | 2002-06-10 | 2013-01-16 | Vaccinex, Inc. | C35 antibodies and their use in the treatment of cancer |
| WO2005099361A2 (en) | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| US20050158323A1 (en) * | 2003-12-04 | 2005-07-21 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
-
2001
- 2001-04-04 CA CA002413211A patent/CA2413211A1/en not_active Abandoned
- 2001-04-04 WO PCT/US2001/010855 patent/WO2001074859A2/en not_active Ceased
- 2001-04-04 NZ NZ522282A patent/NZ522282A/en unknown
- 2001-04-04 JP JP2001572548A patent/JP2004502408A/ja active Pending
- 2001-04-04 EP EP01926595A patent/EP1272636B8/en not_active Expired - Lifetime
- 2001-04-04 CN CNA018178049A patent/CN1610743A/zh active Pending
- 2001-04-04 AU AU2001253119A patent/AU2001253119B2/en not_active Ceased
- 2001-04-04 AT AT01926595T patent/ATE404669T1/de not_active IP Right Cessation
- 2001-04-04 US US09/824,787 patent/US7268207B2/en not_active Expired - Fee Related
- 2001-04-04 DE DE60135315T patent/DE60135315D1/de not_active Expired - Lifetime
- 2001-04-04 AU AU5311901A patent/AU5311901A/xx active Pending
- 2001-04-04 CN CN200910007590A patent/CN101643732A/zh active Pending
-
2006
- 2006-11-20 US US11/601,669 patent/US20070081942A1/en not_active Abandoned
-
2009
- 2009-02-26 US US12/393,860 patent/US7910551B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502408A5 (enExample) | ||
| EP2945647B1 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| JP5393144B2 (ja) | Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| US11859015B2 (en) | Immunogenic WT-1 peptides and methods of use thereof | |
| KR20010053180A (ko) | 시클로필린 ｂ 유래의 종양 항원 펩티드 | |
| PT1650221E (pt) | Novos compostos | |
| JP2014533095A5 (enExample) | ||
| US6737062B2 (en) | Immunogenic compositions | |
| JPWO2020071551A5 (enExample) | ||
| US7071294B1 (en) | Tumor antigen protein art-1 and tumor antigen peptide thereof | |
| JP2002538166A (ja) | Ｍｈｃクラスｉｉによって提示されるｍａｇｅ−３由来免疫原性ペプチドおよびその使用 | |
| CN105531368A (zh) | 肿瘤抗原肽 | |
| JP2003522195A (ja) | 肝細胞癌の治療のための方法及び組成物 | |
| JP2002539826A (ja) | 新規化合物 | |
| WO2002006338A1 (en) | Vaccine comprising a lung tumour associated antigen | |
| NZ509585A (en) | HLA-A2 restraint tumor antigen peptide orignating in SART-1 | |
| US6809179B1 (en) | Tumor-associated antigen (R11) | |
| WO2007039716A1 (en) | T cell epitopes from the 5t4 tumor associated antigen and their use in treatment of cancer | |
| US20040138135A1 (en) | Therapeutic compounds for ovarian cancer | |
| US7476535B2 (en) | TRP2 isoform TRP2-6b containing HLA-A2 restricted epitopes | |
| CA2387043A1 (en) | Colon-tumour-associated antigens | |
| EP2330122A1 (en) | OFA/iLRP derived modified peptide | |
| Seliger et al. | Cytotoxic T Cell Epitopes and Tissue | |
| CA2416890A1 (en) | Therapeutic anti-melanoma compounds | |
| US20050059056A1 (en) | Antigenic gp100 (154-162) compounds for therapy and diagnosis and methods for using same |